BACKGROUND: Oncolytic adenoviruses provide a promising alternative for cancer treatment. Recently, adjuvant interferon (IFN)-alfa has shown significant survival benefits for pancreatic cancer, yet was impeded by systemic toxicity. To circumvent these problems adenovirus with high-level targeted IFN-alfa expression can be generated. METHODS: Conditionally replicative adenoviruses (CRAds) with improved virulence and selectivity for pancreatic cancer were generated. The vectors were tested in vitro, in vivo, and in human pancreatic cancer and normal tissue specimens. RESULTS: Adenoviral death protein and fiber modifications significantly improved oncolysis. CRAds selectively replicated in vitro, in vivo and showed persistent spread in cancer xenografts. They showed high-level replication in human pancreatic cancer specimens, but not in normal tissues. Improved IFN-CRAd oncolytic efficiency was shown. CONCLUSIONS: Optimized cyclooxygenase-2 CRAds show highly favorable effects in vitro and in vivo. We report a pancreatic cancer-specific, highly virulent, IFN-expressing CRAd, and we believe that adenovirus-based IFN therapy offers a new treatment opportunity for pancreatic cancer patients.
BACKGROUND: Oncolytic adenoviruses provide a promising alternative for cancer treatment. Recently, adjuvant interferon (IFN)-alfa has shown significant survival benefits for pancreatic cancer, yet was impeded by systemic toxicity. To circumvent these problems adenovirus with high-level targeted IFN-alfa expression can be generated. METHODS: Conditionally replicative adenoviruses (CRAds) with improved virulence and selectivity for pancreatic cancer were generated. The vectors were tested in vitro, in vivo, and in humanpancreatic cancer and normal tissue specimens. RESULTS:Adenoviral death protein and fiber modifications significantly improved oncolysis. CRAds selectively replicated in vitro, in vivo and showed persistent spread in cancer xenografts. They showed high-level replication in humanpancreatic cancer specimens, but not in normal tissues. Improved IFN-CRAd oncolytic efficiency was shown. CONCLUSIONS: Optimized cyclooxygenase-2 CRAds show highly favorable effects in vitro and in vivo. We report a pancreatic cancer-specific, highly virulent, IFN-expressing CRAd, and we believe that adenovirus-based IFN therapy offers a new treatment opportunity for pancreatic cancerpatients.
Authors: Masato Yamamoto; Julia Davydova; Minghui Wang; Gene P Siegal; Victor Krasnykh; Selwyn M Vickers; David T Curiel Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: J Randolph Hecht; Rudolph Bedford; James L Abbruzzese; Sandeep Lahoti; Tony R Reid; Roy M Soetikno; David H Kirn; Scott M Freeman Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; Peter Krajcsi; Ann E Tollefson; William S M Wold Journal: Virology Date: 2003-01-20 Impact factor: 3.616
Authors: Julia Davydova; Long P Le; Tatyana Gavrikova; Minghui Wang; Victor Krasnykh; Masato Yamamoto Journal: Cancer Res Date: 2004-06-15 Impact factor: 12.701
Authors: F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb Journal: Hum Gene Ther Date: 1996-01-20 Impact factor: 5.695
Authors: Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova Journal: Surgery Date: 2015-02-27 Impact factor: 3.982